Research To Practice | Oncology Videos

Featuring an interview with Dr Mansoor Raza Mirza, including the following topics: Delivery of care models for endometrial cancer (0:00) Molecular profiling and treatment for endometrial cancer (1:57) Current use of immunotherapy for the management of endometrial cancer (8:56) Mitigating and managing immunotherapy-associated adverse events for patients with endometrial cancer (13:40) Immune checkpoint inhibitors for localized endometrial cancer(18:51) Practical considerations in the care of patients with endometrial cancer (22:17) Targeted therapy for patients with endometrial cancer (30:08) CME information and select publications

Featuring a slide presentation and related discussion from Dr Mansoor Raza Mirza, including the following topics: Molecular classification of endometrial cancer and immunotherapy options for patients with microsatellite instabiliity-high/DNA mismatch repair deficient endometrial cancer (0:00) Immunotherapy for mismatch repair-proficient endometrial cancer (9:18) Ongoing Phase III trials evaluating immunotherapy for endometrial cancer (18:11) CME information and select publications

Featuring perspectives from Dr John Strickler, including the following topics: Introduction (0:00) Case: A man in his early 60s with gastroesophageal junction (GEJ) adenocarcinoma who responds to neoadjuvant chemoradiation therapy but declines surgery and develops progressive disease (HER2 1+, PD-L1 2%) — Minesh Dinubhai Patel, MD (13:54) Case: A frail woman in her late 80s with unresectable gastric cancer who chooses to receive systemic therapy (PD-L1 0%, HER2 negative, MSS) — Matthew R Strickland, MD (18:20) Case: A man in his mid 60s with T3N1M mixed gastric adenocarcinoma who responds well to neoadjuvant FLOT and has minimal residual disease at surgery — Ranju Gupta, MD (23:01) Case: A man in his early 60s with a history of prostate cancer who is now diagnosed with T2N1M0, HER2-positive GEJ adenocarcinoma — Dr Strickland (29:23) Case: A man in his early 30s with metastatic HER2-positive gastric adenocarcinoma who is responding well to FOLFOX, trastuzumab and nivolumab — Priya Rudolph, MD, PhD (33:00) Case: A man in his early 60s with metastatic HER2-positive esophageal cancer and a germline CHEK2 mutation who experiences disease progression on chemotherapy, pembrolizumab, trastuzumab and later T-DXd (PD-L1 12%) — Warren S Brenner, MD (46:34) Case: A man in his mid 70s with symptomatic anemia who is diagnosed with metastatic esophageal adenocarcinoma (PD-L1 8%, MSS, HER2 1+) — Dr Strickland (55:44) Case: A woman in her early 60s with squamous cell esophageal carcinoma metastatic to bone (PD-L1 TPS 10%) — Dr Strickland (58:46) CME information and select publications

Featuring a slide presentation and related discussion from Dr Asim Farooq, including the following topics: Molecular classification of endometrial cancer and immunotherapy options for patients with microsatellite instabiliity-high/DNA mismatch repair deficient endometrial cancer (0:00) Immunotherapy for mismatch repair-proficient endometrial cancer (9:18) Ongoing Phase III trials evaluating immunotherapy for endometrial cancer (18:11) CME information and select publications

Featuring an interview with Dr Asim Farooq, including the following topics: Educating patients about ocular toxicities associated with anticancer therapies (0:00) Differentiating therapy-related ocular toxicities from symptoms not associated with anticancer drugs (3:44) Optimal prevention of ocular toxicities from antibody-drug conjugates; symptoms and management of central serous retinopathy (9:36) Pathophysiology of ocular symptoms associated with ALK inhibitors and BRAF/MEK inhibitors (16:40) Myths and misperceptions among physicians about ophthalmic toxicities (22:29) CME information and select publications

Featuring perspectives from Dr Stephen Liu, including the following topics: Introduction: Journal Club with Stephen V Liu, MD (0:00) Case: A woman in her mid 40s with metastatic lung adenocarcinoma with a ROS1 fusion — Minesh Dinubhai Patel, MD (10:54) Case: A woman in her late 70s with metastatic lung adenocarcinoma with a HER2 mutation — Adam R Miller, MD (17:40) Case: A woman in her early 60s with RET-fusion-driven lung adenocarcinoma — Kapisthalam (KS) Kumar, MD (22:30) Case: A woman in her early 70s with metastatic adenocarcinoma of the lung with a MET exon 14 mutation — Dr Kumar (31:02) Case: A woman in her early 70s with recurrent lung adenocarcinoma with a MET T263M mutation — Priya Rudolph, MD, PhD (34:15) Case: A woman in her late 70s with metastatic adenocarcinoma with a MET exon 14 mutation — Gigi Chen, MD (39:53) Case: A woman in her late 70s with ALK fusion-driven lung adenocarcinoma — Rajni Sinha, MD, MRCP (45:52) Case: A woman in her late 60s with metastatic lung adenocarcinoma and a KRAS G12C mutation — Dr Miller (52:08) Case: A woman in her early 60s with metastatic lung adenocarcinoma and an NRG1 fusion — Jiaxin (Jason) Niu, MD, PhD (57:06) CME information and select publications

Featuring perspectives from Drs Ajai Chari, Ian Flinn, Nikhil Munshi and Laurie Sehn, including the following topics: Part 1: Case Presentations and Clinical Decision-Making (0:00) Case: A man in his early 70s with diffuse large B-cell lymphoma (DLBCL) arising from follicular lymphoma — Ian W Flinn, MD, PhD (3:46) Case: A man in his late 50s with nongerminal center B-cell-like subtype DLBCL — Laurie H Sehn, MD, MPH (15:57) Case: CAR-T therapy during the pandemic — Nikhil C Munshi, MD (22:16) Case: Anti-BCMC bispecific in triple-class and penta-drug refractory disease — Ajai Chari, MD (33:54) CAR-T therapy for non-Hodgkin lymphoma — Dr Flinn (37:09) Bispecifics for non-Hodgkin lymphoma — Dr Sehn (51:48) CAR-T therapy for multiple myeloma — Dr Munshi (1:13:23) Bispecifics for multiple myeloma — Dr Chari (1:26:14) CME information and select publications

Featuring perspectives from Prof Jonathan Ledermann, including the following topics: Introduction (0:00) Case: An Asian woman in her early 80s with ovarian cancer and a gBRCA mutation receiving maintenance olaparib after surgery and adjuvant chemotherapy — Rao Mushtaq, MD (2:05) Journal Club with Prof Ledermann (7:58) Case: A woman in her mid 80s with gBRCA wild-type high-grade serous ovarian cancer (HGSOC) who develops recurrent disease after declining maintenance niraparib — Priya Rudolph, MD, PhD (17:28) Antibody-Drug Conjugates for Ovarian Cancer (23:09) Case: A woman in her mid 70s with HGSOC and gBRCA1 and 2 mutations who responds to olaparib for 5 years but then develops progressive disease after stopping — Karim ElSahwi, MD (33:38) Case: A woman in her late 60s with gBRCA wild-type Stage IIIC ovarian cancer who receives IV/IP adjuvant chemotherapy — Gigi Chen, MD (43:19) Case: A woman in her mid 40s with microsatellite instability-high BRCA wild-type clear cell ovarian cancer with stable disease on pembrolizumab — Syed F Zafar, MD (47:59) Case: A woman in her late 50s with recurrent BRCA wild-type (HRp) low-grade ovarian cancer with rising CA-125, pleural effusion and a new lung nodule on salvage chemotherapy — Dana M Chase, MD (52:48) Case: A woman in her early 90s with past medical history of untreated chronic lymphocytic leukemia who presents with Stage III/IV ovarian cancer — Rajalaxmi McKenna, MD (56:45) CME information and select publications

Proceedings from a daylong multitumor educational symposium in partnership with the American Oncology Network, featuring perspectives from Drs Ibiayi Dagogo-Jack and Suresh Ramalingam on recent advances and real-world implications in lung cancer. CME information and select publications

Proceedings from a daylong multitumor educational symposium in partnership with the American Oncology Network, featuring perspectives from Drs Brad S Kahl and Craig Moskowitz on recent advances and real-world implications in chronic lymphocytic leukemia and lymphomas. CME information and select publications

Proceedings from a daylong multitumor educational symposium in partnership with the American Oncology Network, featuring perspectives from Drs Rafael Fonseca and Krina Patel on recent advances and real-world implications in multiple myeloma. CME information and select publications

Proceedings from a daylong multitumor educational symposium in partnership with the American Oncology Network, featuring perspectives from Drs Neeraj Agarwal and Sandy Srinivas on recent advances and real-world implications in genitourinary cancers. CME information and select publications

Proceedings from a daylong multitumor educational symposium in partnership with the American Oncology Network, featuring perspectives from Drs Harold Burstein and Joyce O'Shaughnessy on recent advances and real-world implications in breast cancer. CME information and select publications

Featuring a slide presentation and related discussion from Dr Joshua Sabari, including the following topics: Recent updates from ASCO 2022 in the use of EGFR- and MET-targeted therapies (0:00) Targeting HER3 in patients with advanced non-small cell lung cancer (NSCLC) with and without EGFR mutations (16:04) Recent updates in therapy for patients with EGFR exon 20 insertion mutations (21:47) DESTINY-Lung04 trial: Trastuzumab deruxtecan for patients with HER2 exon 19 or 20 mutations (2921) Using mutational status in predicting patient benefit from chemoimmunotherapy (34:51) Immune checkpoint inhibition for patients with NSCLC with EGFR mutations (38:41) Combining novel agents with immune checkpoint inhibitors for patients with NSCLC and high PD-L1 expression (47:36) CME information and select publications

Featuring an interview with Dr Joshua Sabari, including the following topics: Updates in the use of adjuvant targeted therapy for localized and metastatic non-small cell lung cancer (NSCLC); impact of the ADAURA trial (0:00) Factors in the selection of second-line therapy for patients with and without driver mutations (10:30) Role of immunotherapy for patients with driver mutations (14:26) Recent updates in the use of antibody-drug conjugates for NSCLC (17:01) Combining VEGF inhibition with other therapies for previously treated NSCLC (20:10) Factors affecting response to immunotherapy in patients with lung cancer (23:19) CME information and select publications

Proceedings from a daylong multitumor educational symposium in partnership with the American Oncology Network, featuring perspectives from Drs Rutika Mehta and Philip Philip on recent advances and real-world implications in gastrointestinal cancers. CME information and select publications

Featuring a slide presentation and related discussion from Dr Alexander Spira, including the following topics: Incidence and spectrum of KRAS mutations in non-small cell lung cancer (NSCLC) (0:00) Sotorasib for the treatment of NSCLC with a KRAS G12C mutation (2:06) Clinical data evaluating adagrasib for the treatment of NSCLC with a KRAS G12C mutation (9:44) Future directions in the care of patients with NSCLC with KRAS mutations (22:17) Case: A man in his early 70s with relapsed NSCLC with a G12C mutation (26:26) Case: A man in his mid 60s with newly diagnosed metastatic NSCLC with a KRAS G12C mutation (27:53) CME information and select publications

Featuring perspectives from Dr Alexander Spira, including the following topics: KRAS mutations in patients with non-small cell lung cancer (NSCLC) (0:00) KRAS small-molecule inhibitors combined with targeted therapy or immunotherapy for patients with NSCLC (3:49) KRAS small-molecule inhibitors in patients with NSCLC and brain metastases (10:52) Future role of KRAS small-molecule inhibitors as adjuvant or neoadjuvant therapy for patients with localized NSCLC (12:21) Comparing and contrasting KRAS small-molecule inhibitors for NSCLC (14:56) Future directions in targeting KRAS and other mutations (20:32) Using liquid biopsy to detect KRAS-mutated NSCLC (33:01) Common misperceptions about targeting KRAS G12C in NSCLC (35:43) CME information and select publications

Featuring perspectives from Dr Robin "Katie" Kelley, including the following topics: Introduction (0:00) Case: A man in his mid 80s with newly diagnosed hepatocellular carcinoma (HCC) who has a partial response with atezolizumab/bevacizumab — Minesh Dinubhai Patel, MD (15:01) Case: A man in his mid 60s with HCC and lung metastases (AFP = 30,000) who receives front-line atezolizumab/bevacizumab — Warren S Brenner, MD (30:17) Case: A man in his mid 60s with metastatic HCC and rapid disease progression on first-line atezolizumab/bevacizumab — Shaachi Gupta, MD, MPH (34:56) Case: A man in his early 80s with NASH liver cirrhosis and advanced HCC who develops proteinuria on atezolizumab/bevacizumab — Liudmila N Schafer, MD (39:09) Journal Club with Dr Kelley (42:53) Case: A woman in her early 70s with metastatic pancreaticobiliary cancer thought to be intrahepatic cholangiocarcinoma — Priya Rudolph, MD, PhD (48:39) Case: A woman in her late 40s with intrahepatic cholangiocarcinoma and micrometastases in portal lymph nodes — Pavel A Levin, MD, PhD (59:13) CME information and select publications

Featuring a slide presentation and related discussion from Dr Brian Slomovitz, including the following topics: Recent data with PARP inhibitors alone and in combination with other agents as maintenance therapy for advanced ovarian cancer; recent data with novel agents (0:00) Efficacy data with pembrolizumab/chemotherapy from the KEYNOTE-826 trial; biologic rationale for targeting tissue factor and emerging data with tisotumab vedotin for cervical cancer (16:45) PFS2 data (disease progression on next line of therapy after first progression) with lenvatinib/pembrolizumab for advanced endometrial cancer; recent data with dostarlimab and mTOR inhibitors (23:58) CME information and select publications

Featuring an interview with Dr Brian Slomovitz, including the following topics: Comparative efficacy and safety of commercially available PARP inhibitors for ovarian cancer (OC) (0:00) Patient- and disease-specific considerations in the selection and sequencing of treatment for OC with BRCA mutations (11:39) Mechanism of action of mirvetuximab soravtansine; recent efficacy and safety data with mirvetuximab for platinum-resistant OC from the SORAYA trial (15:13) Potential integration of mirvetuximab soravtansine into the treatment algorithm for platinum-resistant OC; emerging data with niraparib/dostarlimab and adavosertib for OC (20:23) Ongoing clinical trials evaluating tumor treating fields and upifitamab rilsodotin for OC (24:57) Recent follow-up data with pembrolizumab/bevacizumab/chemotherapy for metastatic cervical cancer (CC) from the KEYNOTE-826 trial (27:30) Efficacy and safety data with lenvatinib/pembrolizumab from the KEYNOTE-775 trial for endometrial cancer (EC); benefit of lenvatinib/pembrolizumab in subsequent lines of therapy (32:13) Updated data with dostarlimab for microsatellite instability (MSI)-high EC; ongoing clinical trials evaluating immunotherapy versus chemotherapy alone for MSI-high EC (35:47) HER2-low data with T-DXd for breast cancer and its potential role in therapy for EC; emerging role of mTOR inhibitors; ongoing investigations and unmet needs in OC, CC and EC (40:01) CME information and select publications

Featuring perspectives from Dr Samuel Klempner, including the following topics: Introduction (0:00) Case: A man in his mid 70s with gastric adenocarcinoma and oligometastatic disease to the liver (PD-L1 10%, HER2-positive) — Ranju Gupta, MD (2:47) Case: A man in his early 70s with locally advanced HER2-positive gastroesophageal junction (GEJ) adenocarcinoma who undergoes chemoradiation therapy and surgery but develops progressive disease on adjuvant nivolumab and is now receiving CAPOX with trastuzumab (PD-L1 10%, microsatellite stable [MSS]) — Bruce Bank, MD (9:39) Treatment of Microsatellite Instability-High Disease (20:46) Case: A woman in her late 60s with GEJ adenocarcinoma metastatic to the liver (MSS, PD-L1 2%, HER2-negative) — Warren S Brenner, MD (36:32) Case: A man in his late 50s with GEJ adenocarcinoma who receives neoadjuvant fluorouracil/leucovorin/oxaliplatin/docetaxel (FLOT), is found to have 8/18 positive nodes at surgery, receives adjuvant FLOT and currently has no evidence of disease (PD-L1 Case: A man in his early 50s with esophageal adenocarcinoma with an FDG-avid mediastinal node who undergoes chemoradiation therapy and definitive radiation therapy to the node (MSS, PD-L1 0%, HER2-negative) — Jennifer L Dallas, MD (48:55) Case: A man in his mid 50s with a history of Barrett's esophagus with T1bNXM0 adenocarcinoma with signet cell features who undergoes endoscopic resection and declines esophagectomy — Matthew R Strickland, MD (53:11) Case: A man in his early 60s with a 70-lb weight loss and locally advanced high-grade neuroendocrine carcinoma of the distal esophagus — Dr Gupta (56:58) CME information and select publications

Featuring an interview with Dr Ezra Cohen, including the following topics: Spectrum of targetable mutations in thyroid cancer and impact on treatment selection (0:00) Comparative efficacy of TRK inhibitors in patients with thyroid cancer, including those with CNS disease (6:06) Current and emerging roles of immunotherapy alone and in combination with tyrosine kinase inhibitors for patients with head and neck cancer (10:17) Predicting clinical response to immunotherapy for patients with head and neck cancers (19:47) Role of dose reduction in managing toxicities associated with immunotherapy and targeted agents (26:01) Current and potential roles for cell-free DNA testing and minimal residual disease assessment in the management of head and neck cancer (32:08) Recently reported efficacy data with avasopasem in the treatment of radiation-induced oral mucositis (35:27) Factors affecting response to immunotherapy (42:07) CME information and select publications

Featuring a slide presentation and related discussion from Dr Ezra Cohen, including the following topics: Current standard therapy for head and neck cancer (0:00) Emerging data from clinical trials in head and neck cancer (3:41) Current standard therapy and recent research data in thyroid cancer (15:35) CME information and select publications

Featuring perspectives from Dr Daniel DeAngelo, including the following topics: Introduction: Perspectives on chronic myeloid leukemia (CML) (0:00) Asciminib — ASC4FIRST study (8:33) Case: A woman in her early 60s with a PMH of Stage IA hormone receptor-positive breast cancer on adjuvant tamoxifen with newly diagnosed CML — Michael R Grunwald, MD (22:38) Case: A man in his mid 40s with low-risk CML who achieves MR4 on imatinib but loses molecular response 3 months after discontinuing therapy — Shams Bufalino, MD (27:23) Case: A man in his early 40s with CML on dasatinib who does not achieve treatment milestone (MR3) at 18 months but does at 24 months — Dr Grunwald (33:19) Case: A man in his early 80s with CML who initially receives imatinib followed by nilotinib develops CHF and has a BCR-ABL of 0.8% (IS) — Namrata I Peswani, MD (37:33) Case: A woman in her late 20s with CML that is resistant to multiple TKIs and therapy compliance concerns — Minesh Dinubhai Patel, MD (40:44) Case: A woman in her early 40s who initially receives dasatinib for chronic-phase CML with a good response but then develops lymphoid blast crisis — Dr Grunwald (52:17) Case: A woman in her mid 70s with CML who achieves MMR on nilotinib but then develops peripheral arterial occlusion after 9 years on therapy — Dr Grunwald (58:10) CME information and select publications

Featuring perspectives from Dr Ursula Matulonis, including the following topics: Introduction: Journal Club with Ursula Matulonis, MD — Part 1 (0:00) Case: A woman in her late 60s with primary peritoneal carcinoma with a germline BRCA mutation who underwent naturopathic therapy — Dana M Chase, MD (31:08) Case: A woman in her late 70s with Stage IIIC fallopian tube cancer (homologous recombination proficient [HRp]) who underwent neoadjuvant chemotherapy — Paul DiSilvestro, MD (33:55) Case: A woman in her late 60s with high-grade serous ovarian carcinoma and extensive peritoneal and omental metastases (HRp) who received chemotherapy and bevacizumab followed by niraparib — Vikas Malhotra, MD (38:50) Case: A woman in her mid 70s with a germline BRCA1 mutation and bilateral breast cancer who experiences a complete response for 8 years to chemotherapy for metastatic ovarian cancer — Bruce Bank, MD (46:38) Faculty Survey (49:46) Journal Club with Dr Matulonis — Part 2 (54:02) Case: A woman in her mid 40s who experienced multiple relapses of microsatellite instability-high clear cell ovarian cancer — Syed F Zafar, MD (57:38) CME information and select publications

Efficacy data with T-DXd from the DESTINY-Breast04 trial for patients with HER2-low breast cancer; incidence and biologic relevance of HER2 mutations in breast cancer (0:00) Current and potential clinical roles for liquid biopsy in breast cancer; cardiac toxicity with T-DXd in the DESTINY-Breast04 trial (6:10) Safety profile of T-DXd from the DESTINY-Breast04 trial (11:09) Incidence and management of interstitial lung disease caused by T-DXd (14:54) Disease- and patient-specific factors and other considerations in the sequencing of chemotherapy, antibody-drug conjugates, tyrosine kinase inhibitors, SERDs (selective estrogen receptor degraders) and CDK4/6 inhibitors for breast cancer (21:45) Case: A woman in her early 60s with new lobular Stage II breast cancer 20 years after previous breast cancer on the same side (28:39) Case: A woman in her late 20s with a right breast lump and a strong family history of breast cancer (36:12) Case: A woman in her late 30s presenting with right axillary pain who experiences disease progression on T-DM1 and then receives T-DXd (46:09) Future of novel antibody-drug conjugates alone and in combination with immunotherapy for breast cancer (52:35) CME information and select publications

Featuring a slide presentation and related discussion from Dr Shanu Modi, incluing the following topics: Biology and incidence of HER2-low breast cancer (0:00) Emerging clinical trial data with targeted therapies for HER2-low breast cancer (4:53) Future directions in the treatment of HER2-low breast cancer (16:58) CME information and select publications

Featuring an interview with Drs Jeffrey Bradley and David Spigel, including the following topics: Clinical Investigator Perspectives on the Management of Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC) (0:00) Multimodality Management Options for Patients with Unresectable Stage III NSCLC — Jeffrey Bradley, MD (35:46) Integration of Immune Checkpoint Inhibition into the Management of Unresectable Stage III NSCLC — David R Spigel, MD (1:03:41) Case presentations by Dr Bradley (1:25:27) Case Presentations by Dr Spigel (1:37:44) CME information and select publications

Featuring perspectives from Prof Ghassan Abou-Alfa, including the following topics: Introduction (0:00) Case: A woman in her early 50s with metastatic hepatoid carcinoma of the ovary with an FGFR fusion — Syed M Ahmed, MD, PhD (2:56) Key recent data sets (5:59) Case: A man in his mid 60s with a history of Child-Pugh B cirrhosis and Grade 1 esophageal varices who is receiving atezolizumab/bevacizumab for multifocal HCC — Raji Shameem, MD (22:28) Case: A man in his late 60s with previously treated HCC cirrhosis who is now diagnosed with potentially resectable HCC — Syed F Zafar, MD (29:30) Case: A woman in her late 70s receiving adjuvant anastrozole for Stage I breast cancer who is now receiving atezolizumab/bevacizumab for metastatic HCC — Sunil Gandhi, MD (33:41) Case: A man in his late 70s with metastatic HCC and portal vein thrombosis receiving atezolizumab/bevacizumab (NGS [next-generation sequencing] with PIK3CA mutation, PD-L1 50%) — Susmitha Apuri, MD (35:47) Management of Biliary Tract Cancers (40:18) Case: A man in his late 50s with resected Stage IIB gallbladder cancer s/p adjuvant capecitabine who now has metastatic disease (HER2-positive; MSS, PD-L10) — Nasfat Shehadeh, MD (44:01) Case: A woman in her early 40s with a history of ductal carcinoma in situ and family history of breast cancer, now with metastatic cholangiocarcinoma (NGS with IDH2 mutation) — Joanna Metzner-Sadurski, MD (53:41) CME information and select publications

Featuring a slide presentation and related discussion from Dr Sandy Srinivas, including the following topics: Results from the Phase II SALV-ENZA trial evaluating salvage radiation therapy with enzalutamide or placebo for high-risk PSA-recurrent prostate cancer after radical prostatectomy (0:00) Updated overall survival outcomes from the ENZAMET trial of enzalutamide for metastatic hormone-sensitive prostate cancer (3:48) Genomic alterations associated with overall survival for patients with metastatic castration-sensitive prostate cancer treated with apalutamide or placebo with androgen deprivation therapy in the TITAN study (7:43) Three-year overall survival with 177Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer progressing after docetaxel (9:56) Further results from the Phase III PROpel trial of abiraterone with olaparib for patients with metastatic castration-resistant prostate cancer (12:32) Results from the MAGNITUDE study of niraparib with abiraterone acetate and prednisone for metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations (15:39) The role of perioperative chemoimmunotherapy in muscle-invasive urothelial carcinoma (18:23) Long-term outcomes from the Phase III EV-301 trial: Enfortumab vedotin versus chemotherapy for patients with previously treated advanced urothelial carcinoma (21:44) First results from trials of the novel anti-HER2 antibody-drug conjugate RC48 alone and in combination with the anti-PD-1 antibody toripalimab; results from cohorts 3, 4 and 5 of the COSMIC-021 trial evaluating cabozantinib in combination with atezolizumab for urothelial carcinoma (23:12) Updated analyses of exploratory endpoints from the KEYNOTE-564 and CheckMate 9ER trials in renal cell carcinoma (RCC) (26:37) Updates on tyrosine kinase inhibitor and immune checkpoint inhibitor combination therapy and other novel approaches for patients with RCC (29:08) CME information and select publications

Featuring an interview with Dr Sandy Srinivas, including the following topics: Rationale for and efficacy data from the Phase II SALV-ENZA trial of salvage radiation therapy with enzalutamide or placebo for high-risk recurrent hormone-sensitive prostate cancer (0:00) Results from clinical trials evaluating abiraterone, docetaxel or apalutamide for patients with hormone-sensitive prostate cancer (3:29) TheraP trial: Three-year overall survival with 177Lu-PSMA-617 versus cabazitaxel for metastatic hormone-resistant prostate cancer (8:31) Clinical data with abiraterone acetate in combination with PARP inhibition for patients with metastatic hormone-resistant prostate cancer: Results from the PROpel and MAGNITUDE trials (13:54) Current role of neoadjuvant chemotherapy with immunotherapy for patients with metastatic urothelial bladder cancer (UBC); updated long-term outcomes with enfortumab vedotin from the EV-301 trial (20:23) Clinical pearls for preventing and managing adverse events with erdafitinib, sacituzumab govitecan or enfortumab vedotin in patients with UBC (25:23) HER2 expression in UBC and emerging data with the novel HER2-targeted antibody-drug conjugate RC48 alone and in combination with toripalimab; tolerability of antibody-drug conjugates (30:53) Follow-up efficacy and safety data from the KEYNOTE-564 trial; practical implications of the safety data with adjuvant pembrolizumab for renal cell carcinoma (RCC) (36:16) Emerging data with the novel agent belzutifan for advanced clear cell RCC (40:11) Current practice and potential advances in the first-line treatment of metastatic RCC (44:25) CME information and select publications

Featuring perspectives from Dr Richard Stone, including the following topics: Introduction: RATIFY trial in perspective (0:00) Treatment with FLT3 inhibitors (7:00) Anti-CD47 antibody: Magrolimab (23:04) Anti-TIM-3 antibody: Sabatolimab (31:23) CAR T-cell therapy for acute myeloid leukemia (34:53) Targeted therapy with IDH inhibitors (37:31) New myelodysplastic syndromes classification system (41:20) Hypomethylating agents/venetoclax (45:11) CPX-351 (49:14) Other key data sets (50:59) CME information and select publications

Featuring perspectives from Dr Christopher Flowers and Ms Robin Klebig, including the following topics: Management of Diffuse Large B-Cell Lymphoma (0:00) Caring for Patients with Hodgkin Lymphoma (32:59) Treatment for Follicular Lymphoma (44:17) Managing Mantle Cell Lymphoma (58:12) NCPD information and select publications

Featuring a slide presentation and related discussion from Professor Juan Valle, including the following topics: Management of biliary tract cancers (BTCs) with targetable mutations (0:00) Management of BTCs without targetable mutations (13:59) Novel targets and treatments for cholangiocarcinoma and other BTCs (20:19) CME information and select publications

Featuring an interview with Professor Juan Valle, including the following topics: Immunotherapy for patients with biliary tract cancers (BTCs) (0:00) Etiology and presentation of and recent advances in the management of cholangiocarcinoma (4:18) Targeting FGFR alterations in cholangiocarcinoma and other BTCs (12:47) Spectrum and management of toxicities associated with FGFR inhibitors (19:33) Targeting driver mutations beyond FGFR (28:16) Case: A man in his early 60s with intrahepatic cholangiocarcinoma, an FGFR2 fusion and an IDH1 R132C mutation (35:53) Case: A woman in her early 60s with intrahepatic cholangiocarcinoma and an IDH1 mutation that did not respond to third-line ivosidenib (41:49) Case: A woman in her early 60s with gallbladder cancer who received first-line chemotherapy with pembrolizumab (46:15) CME information and select publications

Featuring perspectives from Dr Jorge Cortes, including the following topics: Introduction: Journal Club with Dr Cortes (0:00) Case: A man in his early 40s with chronic myeloid leukemia (CML) and osteopenia after long-term imatinib therapy — Rajalaxmi McKenna, MD (15:00) Case: A man in his early 60s with chronic phase CML (CP-CML) and continued detectable BCR-ABL transcript on bosutinib — Bruce Bank, MD (23:55) Case: A man in his early 70s with CP-CML and notable toxicities from several BCR-ABL tyrosine kinase inhibitors (TKIs) — Gigi Chen, MD (27:37) Case: A woman in her late 40s with CML in complete molecular response for more than 3 years with nilotinib — Michael R Grunwald, MD (36:05) Case: A woman in her mid 60s with CP-CML and negative BCR-ABL mutational analyses who experiences lack of disease response to several BCR-ABL TKIs — Shams Bufalino, MD (43:27) Case: A man in his early 40s with CP-CML who is found to have a T315I mutation — Dr Grunwald (44:45) Appendix of Key Recent Data Sets (53:26) CME information and select publications

Featuring perspectives from Dr Joel Neal, including the following topics: Introduction: Journal Club with Joel W Neal, MD, PhD (0:00) Case: A woman in her mid 60s with Stage I NSCLC with an EGFR mutation and emphysema — Joanna Metzner-Sadurski, MD (18:00) Case: A woman in her late 60s with localized papillary NSCLC with an EGFR L864Q mutation — William R Mitchell, MD (20:42) Case: A woman in her early 70s with Stage IIIA NSCLC and EGFR L858R, ROS1 and TP53 mutations — Neil Morganstein, MD (37:25) Case: A woman in her early 50s with metastatic NSCLC with an EGFR exon 20 insertion (PD-L1 TPS 20%) — Julia Saylors, MD (43:11) Case: A woman in her early 70s with metastatic NSCLC with an EGFR exon 19 mutation (PD-L1 TPS 50%) — Namrata I Peswani, MD (53:53) CME information and select publications

Featuring a slide presentation and related discussion from Dr Angela DeMichele, including the following topics: HER2 and HER3-directed therapies for locally advanced and metastatic breast cancer (0:00) Immunotherapies and antibody-drug conjugates for triple-negative breast cancer and genetic alterations associated with response (13:14) Targeted therapies for estrogen receptor-positive, HER2-negative breast cancer; Response rates by molecular subtypes (25:34) CME information and select publications

Featuring an interview with Dr Angela DeMichele, including the following topics: Staining for HER2 expression and clinical relevance of HER2-0 breast cancer (0:00) Biology of HER2-mutated breast cancer; sequencing of sacituzumab govitecan and trastuzumab deruxtecan for estrogen receptor (ER)-negative breast cancer (4:21) Role of trastuzumab deruxtecan in HER2-low, ER-positive breast cancer; biologic rationale for targeting HER3 with patritumab deruxtecan (11:39) Ongoing clinical trials of tucatinib for HER2-positive locally advanced or metastatic breast cancer: HER2CLIMB-04 and HER2CLIMB-05 (17:16) Recent data with and biomarkers of response for sacituzumab govitecan for triple-negative breast cancer (TNBC); benefits of chemotherapy for disease with a BRCA mutation (22:22) Molecular alterations associated with PARP inhibitor response and potential implications for clinical practice (25:45) Current role of PARP inhibitors, immunotherapy, chemotherapy, and combination therapies for TNBC (28:57) Potential role of sacituzumab govitecan for ER-positive, HER2-negative breast cancer (33:54) Tolerability of capivasertib; using genomic testing to identify tumor subtypes less responsive to endocrine therapy (37:24) Using genomic risk scores to inform treatment for ER-positive, HER2-negative breast cancer that has spread to lymph nodes (43:04) CME information and select publications

Featuring perspectives from Dr Jeff Sharman, including the following topics: Introduction (0:00) Case: A man in his late 50s with progressive small lymphocytic lymphoma who developed acalabrutinib-associated rash — Shams Bufalino, MD (22:14) Case: A man in his late 60s with recurrent deep-vein thrombosis who is receiving warfarin and is diagnosed with chronic lymphocytic leukemia (CLL) requiring treatment — Shaachi Gupta, MD, MPH (27:27) Case: A man in his early 70s with IGHV-unmutated CLL who has severe cardiac disease requiring a defibrillator — Rajalaxmi McKenna, MD (34:45) Case: A man in his early 70s with CLL who remains in remission after treatment with chlorambucil/obinutuzumab — Philip L Brooks, MD (40:43) Case: A man in his early 50s with IGHV-unmutated CLL and del(17p) who developed atrial fibrillation on ibrutinib — Vignesh Narayanan, MD (45:03) Case: A woman in her late 80s with CLL transformed to Hodgkin lymphoma — Spencer H Bachow, MD (51:46) Case: A man in his late 50s with relapsed IGHV-mutated CLL who experienced acalabrutinib-associated headache — Erik Rupard, MD (56:22) Case: A woman in her mid 60s with IGHV-unmutated CLL and hemolytic anemia — Joanna Metzner-Sadurski, MD (1:01:38) CME information and select publications

PARP Inhibition in the Management of Prostate Cancer — Where We Are and Where We're Headed — Faculty Presentation 2: Available Data with, Ongoing Investigation of and Potential Future Role of PARP Inhibitor-Based Combination Strategies — Dr Fred Saad CME information and select publications

PARP Inhibition in the Management of Prostate Cancer — Where We Are and Where We're Headed — Faculty Presentation 1: Optimal Integration of PARP Inhibitor Monotherapy into the Management of Metastatic Castration-Resistant Prostate Cancer — Prof Johann de Bono CME information and select publications

Featuring perspectives from Dr Shannon Westin, including the following topics: Introduction (0:00) Case: A woman in her late 50s with Stage IIIC high-grade serous carcinoma with a gBRCA2 mutation — Gigi Chen, MD (19:58) Case: A woman in her mid 60s with Stage IIA BRCA1/2 wild-type, high-grade serous ovarian adenocarcinoma — Syed M Ahmed, MD, PhD (23:16) Case: A woman in her early 60s with metastatic MSS ovarian carcinoma with a gBRCA1 mutation — Syed Farhan Zafar, MD (30:14) Case: A woman in her early 60s with multiregimen-recurrent advanced ovarian cancer with a gBRCA1 mutation — Rajalaxmi McKenna, MD (39:13) Case: A woman in her early 50s with metastatic hepatoid carcinoma of the ovary with an FGFR fusion — Dr Ahmed (56:54) CME information and select publications

Featuring perspectives from Dr Melissa Johnson, including the following topics: Introduction: KRAS in Lung Cancer (0:00) Case: A woman in her early 60s with adenocarcinoma of the lung and a ROS1 fusion, with bone, brain and leptomeningeal metastases — Gigi Chen, MD (15:52) Case: A man in his late 50s with Stage IVa lung cancer and malignant pleural effusion and a BRAF V600E mutation (PD-L1 60%) — Jiaxin (Jason) Niu, MD, PhD (22:28) Case: A woman in her mid 60s with adenocarcinoma of the lung, a solitary brain metastasis and an ALK fusion — Neil Morganstein, MD (29:33) Case: A woman in her early 50s with metastatic adenocarcinoma of the lung and a RET mutation (PD-L1 TPS 40%) — Rao Mushtaq, MD (36:42) Case: A woman in her early 70s with Stage IV lung adenocarcinoma and malignant pleural effusion and NRG1 fusion — Dr Niu (41:45) Case: A man in his late 60s with metastatic squamous cell carcinoma of the lung with an IDH1 mutation — Sulfi Ibrahim, MD (51:08) MET Exon 14 and HER2 Mutations (54:07) CME information and select publications

Featuring perspectives from Drs Ajai Chari, Elizabeth O'Donnell and Robert Orlowski, including the following topics: Introduction (0:00) Front-Line and Maintenance Treatment Options for Patients with Multiple Myeloma (MM) (2:03) Selection and Sequencing of Therapy for Patients with Relapsed/Refractory MM (28:22) Future Directions in the Management of MM (36:31) CME information and select publications

Featuring perspectives from Prof Eric Van Cutsem, including the following topics: Introduction: Journal Club with Prof Van Cutsem (0:00) Case: A woman in her mid 70s with HER2-negative metastatic gastric cancer (MSI high, PD-L1 >20%) — Nemrata I Peswani, MD (16:51) Case: A man in his mid 70s with multiple comorbidities and HER2-negative metastatic gastroesophageal junction (GEJ) adenocarcinoma (MSS, PD-L1-positive) — Shaachi Gupta, MD, MPD (23:03) Case: A man in his mid 50s with HER2-positive metastatic GEJ adenocarcinoma (PD-L1 low) — Vignesh Narayanan (27:13) Case: A woman in her mid 60s with HER2-equivocal metastatic GEJ adenocarcinoma — Lionel A Kankeu Fonkuoa, MD (30:53) Case: A woman in her mid 60s with HER2-negative metastatic esophageal adenocarcinoma with COPD and vascular disease (pMMR, PD-L1 CPS 5) — Philip L Brooks, MD (46:57) Case: A man in his mid 60s with HER2-negative localized esophageal adenocarcinoma and history of GERD and Barrett's esophagus (pMMR, PD-L1 CPS 1) — Matthew R Strickland, MD (53:18) Case: A man in his early 60s with squamous cell carcinoma of the esophagus who has local and oligometastatic nodal recurrence — Erik Rupard, MD (57:25) CME information and select publications

Featuring a slide presentation and related discussion from Dr Adam Brufsky, including the following topics: Targeted therapies for HER2-expressing breast cancer (0:00) Rationale for targeting HER2-low breast cancer (6:51) Recent data with T-DXd in advanced HER2-low breast cancer (12:57) CME information and select publications

Featuring an interview with Dr Adam Brufsky, including the following topics: Trastuzumab deruxtecan (T-DXd) for HER2-low breast cancer; recently presented findings from the DESTINY-BREAST04 trial (0:00) Impact of heterogeneous disease on the detection of HER2-low expression in patients with breast cancer (7:48) Case: A woman with low-volume, asymptomatic and nonvisceral ER-positive, HER2-low breast cancer (13:16) Case: A woman with high-volume, symptomatic and visceral HER2-low breast cancer; treating ER-negative, HER2-low disease (18:44) Toxicities associated with T-DXd (25:25) Ongoing trials evaluating T-DXd in earlier lines of therapy (31:28) CME information and select publications